Delisting risk
Curis (CRIS)
Develops emavusertib combinations for primary central nervous system lymphoma and chronic lymphocytic leukemia.
$1.40
Pre-market+0.01 (+0.43%)
At close$1.39(−2.11%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
in 63 days
EPS estimate
−$2.29
Revenue estimate
$1.0M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
May '25Aug '25Nov '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$1.25−$0.68−$0.49−$0.49$24.60−$25.00−$4.02Pending
Estimate−$1.14−$39.80−$0.62−$12.40−$11.80−$5.80−$5.70−$2.29
Surprise−9.6%+98.3%+21.0%+96.0%+308.5%−331.0%+29.5%—
RevenueReportedEstimate
May '25Aug '25Nov '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$2.4M$2.7M$3.2M$3.2M$1.1M——Pending
Estimate$2.7M$2.6M$2.9M$2.9M$3.2M$1.7M$1.0M$1.0M
Surprise−10.2%+4.2%+11.0%+11.0%−65.0%———
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$2.29 | — | — |
| Aug 2026 | −$5.70 | −$4.02 | +29.5% |
| May 2026 | −$5.80 | −$25.00 | −331.0% |
| Mar 2026 | −$11.80 | $24.60 | +308.5% |
| Nov 2025 | −$12.40 | −$0.49 | +96.0% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$2.29 | — | — | $1.0M | — | — | — |
| Aug 14, 2026 | −$5.70 | −$4.02 | +29.5% | $1.0M | — | — | −3.7% |
| May 12, 2026 | −$5.80 | −$25.00 | −331.0% | $1.7M | — | — | −9.2% |
| Mar 19, 2026 | −$11.80 | $24.60 | +308.5% | $3.2M | $1.1M | −65.0% | +1.9% |
| Nov 13, 2025 | −$12.40 | −$0.49 | +96.0% | $2.9M | $3.2M | +11.0% | +17.7% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Nov 6, 2025 | |||||||
| Aug 5, 2025 | |||||||
| May 6, 2025 | |||||||
| Mar 31, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 1, 2024 | |||||||
| May 7, 2024 | |||||||
| Mar 11, 2024 | |||||||
| Feb 8, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 4, 2023 | |||||||
| Mar 13, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Feb 24, 2022 | |||||||
| Nov 9, 2021 | |||||||
| Aug 3, 2021 | |||||||
| May 12, 2021 | |||||||
| Mar 16, 2021 | |||||||
| Nov 10, 2020 | |||||||
| Aug 4, 2020 | |||||||
| May 12, 2020 | |||||||
| Mar 19, 2020 | |||||||
| Nov 5, 2019 | |||||||
| Aug 6, 2019 | |||||||
| May 14, 2019 | |||||||
| Mar 26, 2019 | |||||||
| Nov 1, 2018 | |||||||
| Aug 2, 2018 | |||||||
| May 3, 2018 | |||||||
| Mar 8, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 3, 2017 | |||||||
| May 4, 2017 | |||||||
| Mar 9, 2017 | |||||||
| Nov 3, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 9, 2016 | |||||||
| Feb 29, 2016 | |||||||